The goal of bio and pharmaceutical companies has always been to turn healthy ideas into healthy people. Over the past decade, that's become exponentially more difficult. Drug development is more time-consuming and costly, Many patents are expiring in 2014, increasing industry anxiety. Globally, regulatory passage is more stringent. And there are more people to answer to -- payers, physicians, providers and policymakers.

In that time, biotech has exploded. Supercomputing and mapping of the human genome have made possible many potential interesting treatments. But developing biologics is also more complicated and time-consuming.

This is the landscape of the New Health. The destination is a worthy one, but the journey is a harder one. It calls for greater efficiencies, faster outcomes, new sources of capital, smarter ways of assessing risk, global ways of executing. The New Health needs a new kind of ally. Today, Quintiles is helping bio and pharmaceutical companies navigate the way.